Tela Bio Inc. logo

Tela Bio Inc. (TELA)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
0. 73
-0.02
-2.6112%
$
33.6M Market Cap
- P/E Ratio
- Div Yield
17,171 Volume
-1.74 Eps
$ 0.75
Previous Close
Investors:
Add Transaction
Day Range
0.73 0.82
Year Range
0.5 2.19
Want to track TELA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TELA closed today lower at $0.73, a decrease of -2.6112% from yesterday's close, completing a monthly decrease of -19.7585% or -$0.18. Over the past 12 months, TELA stock lost -38.5714%.
TELA is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0483%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

TELA Chart

People also search for

Bioharvest Sciences Inc.
$ 2.7
-4.5936%
GreenLight Biosciences Holdings
$ 0.3
-0.0334%
Sify Technologies Limited Rights expiring 6/21/2024
$ 0.18
+2.0571%
Quantum-Si Inc.
$ 0.2
0%
Rani Therapeutics Holdings Inc.
$ 0.7
+4.0299%
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.25 per share a year ago.

Zacks | 2 months ago
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 months ago
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.23 per share a year ago.

Zacks | 3 months ago

Tela Bio Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Elizabeth Urish
Elizabeth Urish UP STRATEGIC WEALTH INVESTMENT ADVISORS LLC
99,888 $341,261.97 $80,909.28 -$260,352.69 -76.29%
James J. Karabas
James J. Karabas Embree Financial Group
118,178 $153,769.14 $88,692.59 -$65,076.55 -42.32%

Tela Bio Inc. (TELA) FAQ

What is the stock price today?

The current price is $0.73.

On which exchange is it traded?

Tela Bio Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is TELA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 33.6M.

Has Tela Bio Inc. ever had a stock split?

No, there has never been a stock split.

Tela Bio Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Antony Koblish CEO
NASDAQ (NMS) Exchange
872381108 CUSIP
US Country
218 Employees
- Last Dividend
- Last Split
8 Nov 2019 IPO Date

Overview

TELA Bio, Inc. is a commercial-stage medical technology company dedicated to innovating soft-tissue reconstruction solutions that aim to improve clinical outcomes while respecting the patient's anatomy. Established in 2012 and based in Malvern, Pennsylvania, the company targets improving surgical procedures, particularly in the realms of hernia repair, abdominal wall reconstructions, and plastic and reconstructive surgery. TELA Bio has placed emphasis on utilizing a direct sales force to market its products, predominantly within the United States, thereby ensuring a focused and specialized approach towards addressing the needs of its clientele.

Products and Services

TELA Bio has developed a comprehensive portfolio of products designed to meet the diverse needs in soft-tissue reconstruction:

  • OviTex Reinforced Tissue Matrix: This product range is designed for hernia repair and abdominal wall reconstructions. OviTex combines the natural benefits of biological tissue with the strength of synthetic materials, offering a unique solution for these complex procedures. The aim is to provide surgeons with a durable, yet biocompatible option that promotes more natural tissue integration.
  • OviTex PRS Reinforced Tissue Matrix: Specifically tailored for plastic and reconstructive surgery, this product line seeks to address the unmet needs in this specialty. By focusing on the unique requirements of reconstructive surgeries, OviTex PRS provides a reinforced tissue matrix that supports the body's natural healing and tissue integration processes, facilitating better outcomes in a range of reconstructive procedures.
  • OviTex for Laparoscopic and Robotic Procedures: This sterile reinforced tissue matrix is derived from ovine rumen and combined with polypropylene fiber. It is specially designed for use in laparoscopic and robotic-assisted hernia surgical repairs. The innovation lies in its adaptability to minimally invasive surgical techniques, thus offering patients the benefits of shorter recovery times and less post-operative discomfort, while maintaining the strength and reliability needed in hernia repairs.

Contact Information

Address: 1 Great Valley Parkway
Phone: 484 320 2930